Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other financing activities: 2019-2025

Historic Other financing activities for Heron Therapeutics (HRTX) over the last 6 years, with Sep 2025 value amounting to -$51,000.

  • Heron Therapeutics' Other financing activities fell 492.31% to -$51,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $168,000, marking a year-over-year decrease of 50.59%. This contributed to the annual value of $303,000 for FY2024, which is 133.55% up from last year.
  • As of Q3 2025, Heron Therapeutics' Other financing activities stood at -$51,000, which was down 126.29% from $194,000 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Other financing activities ranged from a high of $4.2 million in Q2 2021 and a low of -$637,000 during Q1 2022.
  • Its 3-year average for Other financing activities is -$35,727, with a median of -$2,000 in 2023.
  • In the last 5 years, Heron Therapeutics' Other financing activities plummeted by 1,850.00% in 2024 and then skyrocketed by 481.82% in 2025.
  • Over the past 5 years, Heron Therapeutics' Other financing activities (Quarterly) stood at -$123,000 in 2021, then crashed by 74.80% to -$215,000 in 2022, then spiked by 99.07% to -$2,000 in 2023, then tumbled by 1,850.00% to -$39,000 in 2024, then tumbled by 492.31% to -$51,000 in 2025.
  • Its Other financing activities was -$51,000 in Q3 2025, compared to $194,000 in Q2 2025 and $64,000 in Q1 2025.